Onychomycosis (Tinea Unguium) – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Onychomycosis (Tinea Unguium), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Onychomycosis (Tinea Unguium). Onychomycosis (Tinea Unguium) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
Summary
Global Markets Direct’s, 'Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Onychomycosis (Tinea Unguium), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Onychomycosis (Tinea Unguium). Onychomycosis (Tinea Unguium) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Onychomycosis (Tinea Unguium).
- A review of the Onychomycosis (Tinea Unguium) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Onychomycosis (Tinea Unguium) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
- Identify and understand important and diverse types of therapeutics under development for Onychomycosis (Tinea Unguium).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Onychomycosis (Tinea Unguium) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Onychomycosis (Tinea Unguium) Overview
Therapeutics Development
An Overview of Pipeline Products for Onychomycosis (Tinea Unguium)
Onychomycosis (Tinea Unguium) Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Onychomycosis (Tinea Unguium) Therapeutics – Products under Development by Companies
Companies Involved in Onychomycosis (Tinea Unguium) Therapeutics Development
Valeant Pharmaceuticals International
Stiefel Laboratories, Inc.
Dr. Reddy's Laboratories Limited
Helix BioMedix, Inc.
NexMed, Inc.
NovaBay Pharmaceuticals, Inc.
Nuvo Research Inc.
Hisamitsu Pharmaceutical Co., Inc.
Xel Pharmaceuticals, Inc.
Evolva SA
Novabiotics Ltd
Anacor Pharmaceuticals, Inc.
Topica Pharmaceuticals Inc.
Nitric Biotherapeutics, Inc.
NanoBio Corporation
Promius Pharma, LLC
Moberg Derma AB
Viamet Pharmaceuticals, Inc.
Celtic Pharmaceutical Holdings L.P.
Mayne Pharma Limited
Onychomycosis (Tinea Unguium) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
HB-1275 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
terbinafine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVC-422 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
terbinafine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XEL-003FP - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XEL-003FL - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EV-086 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
luliconazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
efinaconazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVC-612 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tavaborole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AN-2718 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
albaconazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NB-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
itraconazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
itraconazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Novexatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
terbinafine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NAB-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mycosinate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NRI-1002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
terbinafine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MOB-015 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NB-002T - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DRL-NAB-P2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VT-1161 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Onychomycosis (Tinea Unguium) Therapeutics – Drug Profile Updates
Onychomycosis (Tinea Unguium) Therapeutics - Dormant Products
Onychomycosis (Tinea Unguium) – Product Development Milestones
Featured News & Press Releases
Jun 27, 2012: Topica Pharma Initiates Phase IIb/III Study Of Luliconazole In Patients With Onychomycosis Of Toenails
May 31, 2012: NovaBay Pharma Obtains Seven New Patents For Aganocide Compounds
May 22, 2012: Apricus Bio Receives Regulatory Guidance From FDA For MycoVa For Treatment Of Onychomycosis
May 11, 2012: Apricus Bio Announces Pre-NDS Meeting For MycoVa With Health Canada
May 04, 2012: Anacor To Present Clinical Data On Tavaborole At Upcoming Medical Meetings
Mar 30, 2012: Palau Pharma Reports Positive Phase IIb Clinical Results Of Albaconazole For Treatment Of Onychomycosis At American Academy Of Dermatology Annual Meeting
Mar 19, 2012: TOPICA Presents Promising Luliconazole Solution, 10% Data In Onychomycosis At American Academy Of Dermatology
Feb 14, 2012: NovaBiotics Receives US Patent Further Strengthening Novexatin
Feb 09, 2012: Moberg Derma Provides Update On Phase II Study Of MOB-015
Dec 22, 2011: Anacor Pharmaceuticals Completes Enrollment In Second Of Two Phase III Trials Of Tavaborole For Onychomycosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products Under Development for Onychomycosis (Tinea Unguium), H2 2012
Products under Development for Onychomycosis (Tinea Unguium) – Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Comparative Analysis by Pre-Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Valeant Pharmaceuticals International, H2 2012
Stiefel Laboratories, Inc., H2 2012
Dr. Reddy's Laboratories Limited, H2 2012
Helix BioMedix, Inc., H2 2012
NexMed, Inc., H2 2012
NovaBay Pharmaceuticals, Inc., H2 2012
Nuvo Research Inc., H2 2012
Hisamitsu Pharmaceutical Co., Inc., H2 2012
Xel Pharmaceuticals, Inc., H2 2012
Evolva SA, H2 2012
Novabiotics Ltd, H2 2012
Anacor Pharmaceuticals, Inc., H2 2012
Topica Pharmaceuticals Inc., H2 2012
Nitric Biotherapeutics, Inc., H2 2012
NanoBio Corporation, H2 2012
Promius Pharma, LLC, H2 2012
Moberg Derma AB, H2 2012
Viamet Pharmaceuticals, Inc., H2 2012
Celtic Pharmaceutical Holdings L.P., H2 2012
Mayne Pharma Limited, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Onychomycosis (Tinea Unguium) Therapeutics – Drug Profile Updates
Onychomycosis (Tinea Unguium) Therapeutics – Dormant Products
LIST OF FIGURES
Number of Products under Development for Onychomycosis (Tinea Unguium), H2 2012
Products under Development for Onychomycosis (Tinea Unguium) – Comparative Analysis, H2 2012
Products under Development by Companies, H2 2012
Late Stage Products, H2 2012
Mid Clinical Stage Products, H2 2012
Early Clinical Stage Products, H2 2012
Pre-Clinical Stage Products, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Route of Administration, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Molecule Type, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Global Markets Direct Report Coverage
Onychomycosis (Tinea Unguium) Overview
Therapeutics Development
An Overview of Pipeline Products for Onychomycosis (Tinea Unguium)
Onychomycosis (Tinea Unguium) Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Onychomycosis (Tinea Unguium) Therapeutics – Products under Development by Companies
Companies Involved in Onychomycosis (Tinea Unguium) Therapeutics Development
Valeant Pharmaceuticals International
Stiefel Laboratories, Inc.
Dr. Reddy's Laboratories Limited
Helix BioMedix, Inc.
NexMed, Inc.
NovaBay Pharmaceuticals, Inc.
Nuvo Research Inc.
Hisamitsu Pharmaceutical Co., Inc.
Xel Pharmaceuticals, Inc.
Evolva SA
Novabiotics Ltd
Anacor Pharmaceuticals, Inc.
Topica Pharmaceuticals Inc.
Nitric Biotherapeutics, Inc.
NanoBio Corporation
Promius Pharma, LLC
Moberg Derma AB
Viamet Pharmaceuticals, Inc.
Celtic Pharmaceutical Holdings L.P.
Mayne Pharma Limited
Onychomycosis (Tinea Unguium) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
HB-1275 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
terbinafine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVC-422 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
terbinafine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XEL-003FP - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XEL-003FL - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EV-086 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
luliconazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
efinaconazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVC-612 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tavaborole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AN-2718 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
albaconazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NB-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
itraconazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
itraconazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Novexatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
terbinafine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NAB-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mycosinate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NRI-1002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
terbinafine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MOB-015 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NB-002T - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DRL-NAB-P2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VT-1161 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Onychomycosis (Tinea Unguium) Therapeutics – Drug Profile Updates
Onychomycosis (Tinea Unguium) Therapeutics - Dormant Products
Onychomycosis (Tinea Unguium) – Product Development Milestones
Featured News & Press Releases
Jun 27, 2012: Topica Pharma Initiates Phase IIb/III Study Of Luliconazole In Patients With Onychomycosis Of Toenails
May 31, 2012: NovaBay Pharma Obtains Seven New Patents For Aganocide Compounds
May 22, 2012: Apricus Bio Receives Regulatory Guidance From FDA For MycoVa For Treatment Of Onychomycosis
May 11, 2012: Apricus Bio Announces Pre-NDS Meeting For MycoVa With Health Canada
May 04, 2012: Anacor To Present Clinical Data On Tavaborole At Upcoming Medical Meetings
Mar 30, 2012: Palau Pharma Reports Positive Phase IIb Clinical Results Of Albaconazole For Treatment Of Onychomycosis At American Academy Of Dermatology Annual Meeting
Mar 19, 2012: TOPICA Presents Promising Luliconazole Solution, 10% Data In Onychomycosis At American Academy Of Dermatology
Feb 14, 2012: NovaBiotics Receives US Patent Further Strengthening Novexatin
Feb 09, 2012: Moberg Derma Provides Update On Phase II Study Of MOB-015
Dec 22, 2011: Anacor Pharmaceuticals Completes Enrollment In Second Of Two Phase III Trials Of Tavaborole For Onychomycosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products Under Development for Onychomycosis (Tinea Unguium), H2 2012
Products under Development for Onychomycosis (Tinea Unguium) – Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Comparative Analysis by Pre-Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Valeant Pharmaceuticals International, H2 2012
Stiefel Laboratories, Inc., H2 2012
Dr. Reddy's Laboratories Limited, H2 2012
Helix BioMedix, Inc., H2 2012
NexMed, Inc., H2 2012
NovaBay Pharmaceuticals, Inc., H2 2012
Nuvo Research Inc., H2 2012
Hisamitsu Pharmaceutical Co., Inc., H2 2012
Xel Pharmaceuticals, Inc., H2 2012
Evolva SA, H2 2012
Novabiotics Ltd, H2 2012
Anacor Pharmaceuticals, Inc., H2 2012
Topica Pharmaceuticals Inc., H2 2012
Nitric Biotherapeutics, Inc., H2 2012
NanoBio Corporation, H2 2012
Promius Pharma, LLC, H2 2012
Moberg Derma AB, H2 2012
Viamet Pharmaceuticals, Inc., H2 2012
Celtic Pharmaceutical Holdings L.P., H2 2012
Mayne Pharma Limited, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Onychomycosis (Tinea Unguium) Therapeutics – Drug Profile Updates
Onychomycosis (Tinea Unguium) Therapeutics – Dormant Products
LIST OF FIGURES
Number of Products under Development for Onychomycosis (Tinea Unguium), H2 2012
Products under Development for Onychomycosis (Tinea Unguium) – Comparative Analysis, H2 2012
Products under Development by Companies, H2 2012
Late Stage Products, H2 2012
Mid Clinical Stage Products, H2 2012
Early Clinical Stage Products, H2 2012
Pre-Clinical Stage Products, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Route of Administration, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Molecule Type, H2 2012
Assessment by Stage and Molecule Type, H2 2012
